CenterBook Partners LP Purchases 3,537 Shares of Astrazeneca Plc $AZN

CenterBook Partners LP boosted its position in Astrazeneca Plc (NYSE:AZN) by 11.3% in the 4th quarter, Holdings Channel reports. The firm owned 34,800 shares of the company’s stock after buying an additional 3,537 shares during the quarter. CenterBook Partners LP’s holdings in Astrazeneca were worth $6,107,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Lloyd Advisory Services LLC. bought a new stake in Astrazeneca in the fourth quarter worth about $35,000. Basepoint Wealth LLC bought a new stake in Astrazeneca in the fourth quarter worth about $44,000. Nemes Rush Group LLC lifted its stake in Astrazeneca by 162.1% in the fourth quarter. Nemes Rush Group LLC now owns 270 shares of the company’s stock worth $47,000 after purchasing an additional 167 shares during the last quarter. Bangor Savings Bank lifted its stake in Astrazeneca by 102.7% in the fourth quarter. Bangor Savings Bank now owns 304 shares of the company’s stock worth $28,000 after purchasing an additional 154 shares during the last quarter. Finally, Eagle Bay Advisors LLC purchased a new position in shares of Astrazeneca during the fourth quarter worth approximately $30,000. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on AZN. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of Astrazeneca in a research report on Thursday, May 21st. Morgan Stanley reaffirmed an “overweight” rating on shares of Astrazeneca in a research report on Wednesday, April 8th. Wall Street Zen raised shares of Astrazeneca from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings began coverage on shares of Astrazeneca in a research report on Wednesday, March 11th. They set a “buy (b)” rating on the stock. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Astrazeneca in a research report on Wednesday, May 13th. Twelve analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Astrazeneca has an average rating of “Moderate Buy” and a consensus price target of $205.33.

Astrazeneca Stock Performance

Shares of NYSE:AZN opened at $186.06 on Monday. The firm has a market cap of $288.57 billion, a PE ratio of 27.94, a price-to-earnings-growth ratio of 1.59 and a beta of 0.25. The firm’s 50 day simple moving average is $190.84 and its 200-day simple moving average is $185.34. Astrazeneca Plc has a one year low of $137.23 and a one year high of $212.71. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.71 and a current ratio of 0.91.

Astrazeneca (NYSE:AZN) last issued its quarterly earnings data on Wednesday, April 29th. The company reported $2.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.52 by $0.06. The company had revenue of $15.29 billion for the quarter, compared to analyst estimates of $14.93 billion. Astrazeneca had a net margin of 17.19% and a return on equity of 30.86%. As a group, equities analysts predict that Astrazeneca Plc will post 9.52 EPS for the current year.

About Astrazeneca

AstraZeneca plc is a global biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca positions itself as R&D-driven, investing in discovery science, clinical development and regulatory processes to bring new therapies to market.

The company’s commercial portfolio and late-stage pipeline emphasize oncology, cardiovascular, renal and metabolic (CVRM) diseases, and respiratory and immunology.